- Home
- CNTX
as 11-21-2024 4:00pm EST
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 149.6M | IPO Year: | 2021 |
| Target Price: | $6.83 | AVG Volume (30 days): | 210.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $2.75 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Context Therapeutics Inc. News
CNTX Breaking Stock News: Dive into CNTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
GlobeNewswire
a month ago
Context Therapeutics to Participate in Upcoming Investor Conferences in November
GlobeNewswire
a month ago
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
MT Newswires
2 months ago
BioAtla, Context Therapeutics Enter Into License Agreement for BA3362 Cancer Treatment
GlobeNewswire
2 months ago
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
GlobeNewswire
2 months ago
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Simply Wall St.
2 months ago
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
Zacks
2 months ago
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
Compare CNTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTX Context Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.